22nd Century Group, Inc (NASDAQ:XXII) Short Interest Update

22nd Century Group, Inc (NASDAQ:XXII) saw a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 43,168 shares, an increase of 362.6% from the August 15th total of 9,331 shares. Based on an average daily volume of 27,972 shares, the short-interest ratio is presently 1.5 days. Approximately 8.4% of the shares of the company are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in 22nd Century Group stock. Geode Capital Management LLC acquired a new stake in 22nd Century Group, Inc (NASDAQ:XXII) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 46,491 shares of the biotechnology company’s stock, valued at approximately $36,000. Geode Capital Management LLC owned 9.12% of 22nd Century Group at the end of the most recent quarter. 18.06% of the stock is currently owned by institutional investors and hedge funds.

22nd Century Group Trading Down 2.9%

Shares of NASDAQ:XXII opened at $1.99 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.90 and a current ratio of 2.61. The stock’s 50-day moving average is $3.75 and its 200-day moving average is $24.62. The company has a market cap of $1.03 million, a P/E ratio of -0.00 and a beta of 0.60. 22nd Century Group has a 52-week low of $1.93 and a 52-week high of $646.50.

22nd Century Group (NASDAQ:XXII) last posted its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($15.60) earnings per share for the quarter, missing the consensus estimate of ($6.00) by ($9.60). The business had revenue of $2.86 million for the quarter, compared to analyst estimates of $7.48 million. 22nd Century Group had a negative return on equity of 69.37% and a negative net margin of 27.04%.

Analyst Upgrades and Downgrades

XXII has been the subject of a number of analyst reports. Weiss Ratings upgraded shares of 22nd Century Group from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Wall Street Zen raised shares of 22nd Century Group to a “sell” rating in a report on Saturday, June 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, 22nd Century Group currently has a consensus rating of “Sell”.

About 22nd Century Group

22nd Century Group, Inc, founded in 1998 and headquartered in New York, is a plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species. The company’s core mission is to develop and commercialize plant-based solutions that address public health, consumer wellness and agronomic needs. Its flagship reduced nicotine tobacco platform is engineered to deliver significantly lower levels of nicotine than conventional tobacco products while retaining the sensory characteristics sought by adult smokers.

Through its branded reduced nicotine tobacco products, marketed under the NEXT Generation™ portfolio, and its GenCanna® subsidiary focused on hemp cultivation and cannabinoid extraction, 22nd Century serves both commercial markets and contract research clients.